Page 53 - Read Online

Kepka. J Cancer Metastasis Treat 2019;5:53 I http://dx.doi.org/10.20517/2394-4722.2018.114 Page 9 of 11

of radiotherapy with chemotherapy should be further evaluated. It was demonstrated in a randomized trial
that Atezolizumb added to standard chemotherapy with Carboplatin and Etoposide in ES SCLC improved
overall survival, however patients with BM represented only 8.5% of the included cohort . Thus, further
[57]
research is needed to investigate the role of immunotherapy in patients with BM from SCLC.

DECLARATIONS
Authors’ contributions
The author solely contributed to the manuscript.

Availability of data and materials
Not applicable.

Financial support and sponsorship
None.

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES
1. Postmus PE. Brain metastases from small cell lung cancer: chemotherapy, radiotherapy, or both? Semin Radiat Oncol 1995;5:69-73.
2. Kepka L, Cieslak E, Bujko K. Wierzchowski M. Results of the whole-brain radiotherapy for patients with brain metastases from lung
cancer: the RTOG RPA intra-classes analysis. Acta Oncol 2005;44:389-98.
3. Videtic GM, Adelstein DJ, Mekhail TM, Rice TW, Stevens GH, et al. Validation of the RTOG recursive partitioning analysis (RPA)
classification for small-cell lung cancer-only brain metastases. Int J Radiat Oncol Biol Phys 2007;67:240-3.
4. Postmus PE, Haaxma-Reiche H, Gregor A, Groen HJ, Lewinski T, et al. Brain-only metastases of small cell lung cancer; efficacy of
whole brain radiotherapy. An EORTC phase II study. Radiother Oncol 1998;46:29-32.
5. Postmus PE, Haaxma-Reiche H, Smit EF, Groen HJ, Karnicka H, et al. Treatment of brain metastases of small-cell lung cancer:
comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research
and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000;18:3400-8.
6. Auperin A, Arriagada R, Pignon JP, Le Péchoux C, Gregor A, et al. Prophylactic cranial irradiation for patients with small cell lung
cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 1999;341:476-84.
7. Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, et al. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI)
in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01,
EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet Oncol 2009;10:467-74.
8. Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N
Engl J Med 2007;357:664-72.
9. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation
Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997;37:745-51.
10. Sperduto PW, Kased N, Roberge D, Xu Z, Shanley R, et al. Summary report on the graded prognostic assessment: an accurate and facile
diagnosis-specific tool to estimate survival for patients with brain metastases. J Clin Oncol 2012;30:419-25.
11. Rades D, Dziggel L, Segedin B, Oblak I, Nagy V, et al. The first survival score for patients with brain metastases from small cell lung
cancer (SCLC). Clin Neurol Neurosurg 2013;115:2029-32.
12. Bernhardt D, Adeberg S, Bozorgmehr F, Opfermann N, Hörner-Rieber J, et al. Outcome and prognostic factors in single brain metastases